CeaseCancer

Pancreatic cancer drug treatment, combined with chemotherapy

CeaseCancer is a breakthrough therapy for one of the deadliest cancers, with a clear path to rapid clinical entry—targeting a critical unmet need in a market with no truly effective treatments

Contact us

INNOVATION AT SHEBA MEDICAL CENTER

The Problem

PANCREATIC CANCER IS A CRUEL AND INEVITABLE FATE

- 87% of pancreatic cancer cases are fatal with a median survival time of 11 months
- Usually diagnosed at a late stage, when metastases already spread
- Main treatment is chemotherapy
- Very often cancer returns, resistant to chemotherapy
- All new therapies are largely inefficient, raising survival time by a negligible amount

The Solution

CeaseCancer treatment

- CeaseCancer treatment is based on recombinant human Klotho protein
- It has a unique Mechanism of Action affecting only cancer cells
- It’s efficacy and safety demonstrated in vivo and in vitro
- Synergy with chemotherapy was demonstrated
- CeaseCancer treatment was developed by Prof. Ido Wolf, head of Oncology Division of TLV Medical Center



Recombinant human Klotho and human KL-1 inhibit tumor growth in xenograft mice model (treatments vs control)

The Product

Target Product Profile

- Drug for injection (SC or IV)
- Dosage according to prescription
- Prescribed by doctor
- Dosage according to clinical data

- Prescribed for people diagnosed with pancreatic cancer or after treatment to prevent recurrence



*Illustration

The Market

Pancreatic Cancer Market Size

- Global pancreatic cancer market is expected to reach 7.7$bn dollars by 2030 with a CAGR of 14.1%
- There is an urgent need for new therapies
- CeaseCancer's Edge:
  - Targeted therapy with minimal adverse effects
  - Synergy with current treatments
  - Potential expansion to other cancer types
  - Potential for FDA Fast Track designation



Finance

- The target of the current fundraising round is TO BE DISCLOSED
- The funds will enable reaching an inflection point:
  - Completion of PDx animal model and safety
  - Pre-IND meeting with health authorities (e.g FDA)
- At that point, the engagement of pharma companies is anticipated as well as better access to large funding opportunities, that will enable reaching clinical development